Dr. Wierda on Immunotherapy Agents for Patients With CLL
In Partnership With:
William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).
William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).
Chimerica-antigen receptor (CAR) T-cell therapies are being investigated in clinical trials for patients with CLL, Wierda explains.
Checkpoint inhibitor monoclonal antibodies, which have shown promise and activity in patients with solid tumors, are also being studied in ongoing trials, he adds. Immune manipulation and modulation is a very active area of interest and is a part of oingoing research in CLL.
